Executive summary
US Patent 10,300,065 claims a ticagrelor-based post–myocardial infarction (MI) secondary-prevention regimen that pairs ticagrelor 60 mg twice daily with daily aspirin 75–150 mg, and narrows claim scope through cardiovascular-outcome and bleeding-safety performance criteria, plus specific patient-history qualifiers (MI timing window; ACS etiology; prior ticagrelor loading/90 mg phase). The patent’s practical enforceability risk concentrates on (i) whether accused regimens use the same aspirin dose range and same ticagrelor dose (60 mg BID), (ii) whether they can satisfy an outcome-statistics gating element if the claim is construed as requiring those statistically defined endpoints, and (iii) whether competing generics/biosimilars or label-standard-of-care regimens can be designed around by dosing outside the claimed parameters.
US Patent 10,300,065 ticagrelor 60 mg twice daily aspirin 75-150 mg method claims: what is protected and what is required
US Patent 10,300,065 is drafted as a method-of-treatment patent centered on reducing a composite endpoint of:
- cardiovascular death
- myocardial infarction
- stroke
The core claim architecture follows a typical cardiovascular trial gating strategy: the patent claims not merely a dosing combination, but a dosing method that is tied to measurable trial-like outcomes versus an aspirin-only comparator arm.
Core independent claim scope (Claim 1)
Claim 1 requires, in combination:
- Therapy: administering ticagrelor 60 mg twice daily (BID) in a pharmaceutical composition with a pharmaceutically acceptable carrier.
- Patient condition: patient has a history of myocardial infarction.
- Aspirin co-therapy: patient receives aspirin 75–150 mg daily maintenance dose.
- Comparator-relative effect: the composite endpoint rate is reduced relative to a regimen where the patient receives aspirin 75–150 mg only.
What “reducing the rate” operationally means in prosecution/drafting terms
The patent uses an outcome-comparison framing (“reduced relative to aspirin only”). That structure often invites construction questions:
- Is “reduced” merely inferable from known efficacy of ticagrelor+aspirin, or does it require that the method as performed achieves the enumerated statistical thresholds in dependent claims (Claims 9–15), which can be read as explicit gating elements?
- If an accused regimen differs in comparator population, time horizon, inclusion criteria, or follow-up duration, the claimed “rate reduction relative to aspirin only” may become contestable.
Which patient types and MI timelines limit US 10,300,065 claim coverage?
Claim scope narrows through dependent claims that specify patient-history features.
MI timing windows (Claims 3 and 4)
- Claim 3: MI history occurred at least 12 months before the twice-daily ticagrelor 60 mg regimen begins.
- Claim 4: MI history occurred 12 to 36 months before starting the regimen.
This is a key carve-in. Many real-world ticagrelor prescriptions occur earlier post-ACS or post-revascularization. The patent’s cleanest match is late-stage secondary prevention (post-MI beyond one year).
ACS etiology (Claims 5–8; Claim 18)
- Claim 5: MI resulted from acute coronary syndrome (ACS).
- Claim 18 (separate independent method): covers a patient with or had ACS, still requiring ticagrelor 60 mg BID plus aspirin 75–150 mg, with composite endpoint reduction relative to aspirin only.
Prior ticagrelor phase and loading dosing (Claims 6–8 and 21)
These dependent claims layer “how the regimen was initiated” into infringement analysis:
- Claim 6: prior to the regimen, patient was administered ticagrelor 90 mg BID for a portion of 12 months after ACS.
- Claim 7: prior to the regimen, patient was administered ticagrelor 90 mg BID for 12 months after ACS.
- Claim 8: adds a ticagrelor 180 mg loading dose, then ticagrelor 90 mg BID for part of the 12 months after ACS before switching to 60 mg BID.
- Claim 21: essentially repeats Claim 8’s logic, explicitly stating the 180 mg loading dose and 90 mg BID for a portion of the 12 months post-ACS.
Implication for landscape risk: if an accused product or label-driven regimen does not include (or cannot be shown to include) the 90 mg/180 mg lead-in phase, the dependent claims 6–8 and 21 may not read cleanly, but the independent claim 1/18 may still be asserted if the lead-in phase is not required for the independent scope.
What formulations and tablet excipient ranges are covered by US 10,300,065?
Oral tablet requirement (Claim 16) and composition (Claim 17)
- Claim 16: the ticagrelor 60 mg composition is a tablet administered orally.
- Claim 17: excipient ranges are specified (by weight):
- filler: 20–70%
- binder: 3–6%
- disintegrant: 2–6%
- lubricant: 0.5–1%
Key enforceability angle: this is a formulation-limited dependent claim. It can matter in product-specific challenges:
- A generic ANDA formulation that uses different excipient percentages may avoid Claim 17 while still potentially infringing the method claims if those method claims are asserted independently.
- Conversely, formulation design-arounds may not help if the owner litigates on the method-of-use claims that do not require tablet composition particulars.
What do the performance-and-statistical endpoint limitations actually require?
Claims 9–15 impose outcome and safety conditions that go beyond “reduced” and state numeric or statistical constructs tied to a three-year horizon.
Endpoint and efficacy gating (Claim 9; also Claim 10; Claim 11–15)
Claim 9 contains a long list of alternative satisfaction conditions (a) through (r). These include:
- Absolute risk reduction options (e.g., (m): about 1.27% absolute risk reduction at 3 years).
- Relative risk reduction options (e.g., (n): about 17%).
- Kaplan-Meier rate reductions (e.g., (f): Kaplan-Meier rate about 7.8%; (o): ~1.2% reduction).
- Hazard ratio thresholds (e.g., (g): HR < 1; (j): HR about 0.84 at 3 years; (k): HR 0.74–0.95; (l): 95% CI 0.74–0.95).
- Significance-based options (e.g., (d), (e), (i)).
Interpretation pressure point: The claim is written so that satisfying “at least one” condition among (a)–(r) may suffice. In litigation, this shifts the fact-finding focus to whether an accused regimen’s clinical evidence meets those thresholds, and whether “at three years” and the specific composite endpoint definitions line up with trial-like definitions.
Bleeding-safety gating (Claim 10)
Claim 10 uses similar structure for bleeding outcomes at 3 years, with alternative safety conditions (a) through (n), including:
- hazard ratios for fatal bleeding and intracranial hemorrhage not exceeding 1.0 (or not nominally significantly greater than 1).
- relative risk constraints.
- numeric event rates per 100 patient-years for TIMI major bleeding (e.g., (j): ~0.44).
- numeric increases capped (e.g., difference in Kaplan-Meier rate < 0.05% for fatal bleeding; <0.1% for intracranial hemorrhage).
Combined efficacy + safety (Claims 11–15)
These claims require both efficacy and safety together, e.g.:
- Claim 11: statistically significant composite reduction + no fatal bleeding HR > 1.
- Claim 12: statistically significant composite reduction + no fatal bleeding HR “nominally significantly greater than one.”
- Claim 13: statistically significant composite reduction + no intracranial hemorrhage HR > 1.
- Claim 14: statistically significant composite reduction + no intracranial hemorrhage HR “nominally significantly greater than one.”
- Claim 15: statistically significant composite reduction + no relative risk for fatal bleeding > 1.
Practical consequence: these claims make it harder to argue around by “different patient selection” unless the statistical evidence is also altered.
How does US 10,300,065 compare with typical ticagrelor secondary prevention claim patterns (and where are the carve-outs)?
While specific claim charts are not provided here, US 10,300,065 has a distinctive profile compared to broader ticagrelor combination patents:
- Dose specificity: “ticagrelor 60 mg BID” is a firm anchor. This creates a clear design-around surface by using ticagrelor at different dose intensity or different dosing frequency.
- Aspirin dose range specificity: 75–150 mg daily maintenance dose. If a regimen uses aspirin outside this window, method Claim 1 may not read.
- Patient-history constraints: history of MI; dependent narrowings on timing (≥12 months; 12–36 months) and ACS causation.
- Comparator-relative performance: “reduced relative to aspirin-only” makes infringement tied to relative efficacy.
- Statistical/endpoint gating: dependent claims embed trial-like numeric benchmarks (HR, Kaplan-Meier rates, absolute/relative risk reductions) at a defined time horizon (3 years).
Where carve-outs may occur:
- regimens that change aspirin dose outside 75–150 mg
- regimens that are initiated earlier than the ≥12 month post-MI window, depending on which claims are asserted
- regimens that do not use ticagrelor 60 mg BID
- formulations that avoid tablet excipient ranges (Claim 17) if a formulation-only infringement theory is used
What is the likely patent landscape strategy around US 10,300,065 (licensing, generic entry, and litigation risk)?
Given the patent’s method-of-treatment structure and dose specificity, the landscape typically splits into three litigation risk lanes:
1) ANDA or generic ticagrelor on-dose substitution risk
For generic manufacturers, the enforcement risk is highest when:
- the generic is bioequivalent and used at ticagrelor 60 mg BID, and
- the treated patients are in recognized post-MI secondary prevention populations receiving aspirin 75–150 mg.
Design-around by formulation alone does not neutralize method claims if the method claim does not require specific excipients. The excipient-dependent claim (Claim 17) provides less leverage than dose and regimen-dependent limitations.
2) Carve-out via label differences and clinical practice
If a regimen avoids claimed patient-history timing or uses different aspirin dosing, then:
- dependent claims 3–4 (MI timing) and 5–8 (ACS origin and 90 mg lead-in/180 mg loading) may not read.
- independent claims may still be asserted, but the evidentiary “reduced relative to aspirin only” element could be contested.
3) Evidence-based infringement challenges
Because dependent claims encode specific statistical outcomes at 3 years, an accused regimen’s infringement analysis may become evidence-heavy:
- clinical endpoints and definitions must align
- follow-up duration must align
- bleeding outcomes must match the patent’s safety constraints if those dependent claims are asserted
Key claim-scope map for infringement analysis (US 10,300,065)
What must be present for independent method coverage
- ticagrelor 60 mg BID
- oral administration (not required for Claim 1, required for Claim 16)
- patient has history of MI
- aspirin 75–150 mg daily
- composite endpoint reduced versus aspirin-only regimen
What additional facts strengthen or narrow coverage
- MI timing window (≥12 months or 12–36 months): Claims 3–4
- MI due to ACS: Claim 5
- 90 mg BID lead-in after ACS and/or 180 mg loading: Claims 6–8 and 21
- efficacy statistics at 3 years: Claims 9 and 11–15
- bleeding safety statistics at 3 years: Claim 10 and 11–15
- formulation excipient ranges: Claims 16–17
Key Takeaways
- US 10,300,065 claims a specific ticagrelor regimen: 60 mg BID plus aspirin 75–150 mg daily maintenance, for post-MI/ACS secondary prevention, with reduction in a cardiovascular composite endpoint versus aspirin-only comparator.
- The patent includes trial-style statistical and safety gating at a defined 3-year horizon (hazard ratios, Kaplan-Meier rates, absolute and relative risk reductions, and bleeding safety constraints).
- Enforceability leverage is highest where an accused regimen uses the same dose and aspirin range and treats the same post-MI population. Dependent claims further narrow the covered population and prior dosing history (90 mg lead-in; 180 mg loading).
- Formulation excipient limits exist but sit in dependent claims; they are a secondary design-around surface unless method claims are not asserted.
FAQs
-
Does US 10,300,065 require the 180 mg ticagrelor loading dose to infringe?
No for independent Claim 1. Loading appears in dependent Claims 8 and 21.
-
Can a regimen using aspirin 81 mg vs 100 mg avoid infringement?
Not if within 75–150 mg; the aspirin range is part of Claim 1/18.
-
Is the “composite endpoint reduction” element satisfied automatically by clinical knowledge, or must specific trial-like statistics be met?
The independent claims frame reduction versus aspirin-only; dependent claims 9–15 add explicit statistical/endpoint thresholds that can drive evidence-based infringement arguments.
-
Do tablet excipient changes avoid US 10,300,065?
Only if the dispute is limited to excipient-dependent Claim 17. Method claims do not require the excipient percentages.
-
What is the highest-risk patient segment for enforcement of US 10,300,065?
Patients receiving ticagrelor 60 mg BID long-term post-MI (especially after ≥12 months) on aspirin 75–150 mg daily, where outcomes and bleeding profile align with the patent’s endpoint gating.
References (APA)
No external sources were cited in the provided input.
